Posts Tagged

Featured

01
Jul 2020

COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair

David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
17
Mar 2020

Future Fifty: joining forces to drive forward positive change

BenevolentAI today announced it has been selected for Tech Nation’s 2020 Future Fifty cohort. Our CEO Joanna Shields reflects on how joining forces with like-minded industry experts can serve as a powerful vehicle for transformation.
26
Feb 2020

MIT Technology Review names BenevolentAI as a top 10 breakthrough tech

We’re proud to be recognised on this prestigious list for our work in AI-driven chemical design. Our compound design is based upon complex multiparametric optimisations which aim to cut the time and cost of designing a drug.